Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Malignant Melanoma

  Free Subscription

Articles published in Br J Dermatol

Retrieve available abstracts of 143 articles:
HTML format

Single Articles

    March 2024
  1. TALTY R, Richmond R, Micevic G
    Melanoma TIL therapy commences era of cell-based immunotherapies.
    Br J Dermatol. 2024 Mar 22:ljae126. doi: 10.1093.

  2. AMBRA1 and loricrin as a test to identify low-risk early-stage melanoma.
    Br J Dermatol. 2024;190:e46.

  3. International trends in the incidence of cutaneous squamous cell carcinoma and melanoma.
    Br J Dermatol. 2024;190:e40.

    February 2024
  4. RIBERO S, Quaglino P, Roccuzzo G
    Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
    Br J Dermatol. 2024 Feb 29:ljae092. doi: 10.1093.

  5. EGELER MD, Ryll B
    Survival is not enough: understanding the mental burden of cutaneous melanoma.
    Br J Dermatol. 2024 Feb 3:ljae050. doi: 10.1093.

    January 2024
  6. MUKHTAR AB, Morgan HJ, Gibbs A, Davies GE, et al
    Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
    Br J Dermatol. 2024 Jan 30:ljad502. doi: 10.1093.
    PubMed     Abstract available

    Improving cancer stem cells killing in malignant melanoma.
    Br J Dermatol. 2024 Jan 29:ljae035. doi: 10.1093.

  8. Risk factors for developing a new primary melanoma in people with a melanoma.
    Br J Dermatol. 2024;190:e15.

  9. Genes associated with nodular melanoma.
    Br J Dermatol. 2024;190:e18.

  10. PAPACHRISTOU P, Soderholm M, Pallon J, Taloyan M, et al
    Evaluation of an artificial intelligence-based decision support for detection of cutaneous melanoma in primary care - a prospective, real-life, clinical trial.
    Br J Dermatol. 2024 Jan 17:ljae021. doi: 10.1093.
    PubMed     Abstract available

  11. PENA-MARTIN J, Garcia-Ortega MB, Palacios-Ferrer JL, Diaz C, et al
    Identification of novel biomarkers for early diagnosis of malignant melanoma by untargeted LC-HRMS-based metabolomics: a pilot study.
    Br J Dermatol. 2024 Jan 12:ljae013. doi: 10.1093.
    PubMed     Abstract available

  12. COCCIMIGLIO M, Chiodo F, van Kooyk Y
    The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
    Br J Dermatol. 2024 Jan 10:ljad517. doi: 10.1093.
    PubMed     Abstract available

  13. KUNGWENGWE G, Gowthorpe C, Ali SR, Warren H, et al
    Prevalence & Odds of Anxiety & Depression in Cutaneous Malignant Melanoma: A Proportional Meta-analysis & Regression.
    Br J Dermatol. 2024 Jan 10:ljae011. doi: 10.1093.
    PubMed     Abstract available

    December 2023

  14. Genetics and melanoma screening.
    Br J Dermatol. 2023;190:e4.

  15. EGGERMONT CJ, Eggermont AMM
    Shifting landscape in skin cancer incidence: the rising tide of cutaneous squamous cell carcinoma and potential implications for prevention.
    Br J Dermatol. 2023 Dec 14:ljad480. doi: 10.1093.

    November 2023
  16. MOHR C, Li Y, Navsaria LJ, Hinkston CL, et al
    Melanoma risk in skin of color patients with a history of a keratinocyte carcinoma.
    Br J Dermatol. 2023 Nov 30:ljad474. doi: 10.1093.

  17. EWEN T, Husain A, Stefanos N, Barrett P, et al
    Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
    Br J Dermatol. 2023 Nov 25:ljad459. doi: 10.1093.
    PubMed     Abstract available

  18. KAMMINGA NCW, Wakkee M, Swart I, Nijsten TEC, et al
    Determining the core content of a digital survivorship care plan for melanoma survivors: A multi-stakeholder Delphi-consensus study.
    Br J Dermatol. 2023 Nov 18:ljad450. doi: 10.1093.

  19. DESSINIOTI C, Stratigos AJ
    Decoding the nodular melanoma subtype- what about genetics?
    Br J Dermatol. 2023 Nov 17:ljad445. doi: 10.1093.

  20. Survival trends in people with melanoma in Sweden.
    Br J Dermatol. 2023;189:e108.

  21. SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
    Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors.
    Br J Dermatol. 2023 Nov 8:ljad342. doi: 10.1093.

  22. SMIT AK, Cust AE
    Unpacking factors contributing to melanoma overdiagnosis: does polygenic risk play a role?
    Br J Dermatol. 2023 Nov 6:ljad431. doi: 10.1093.

    October 2023
  23. OLSEN CM, Pandeya N, Ragaini BS, Neale RE, et al
    International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020.
    Br J Dermatol. 2023 Oct 27:ljad425. doi: 10.1093.
    PubMed     Abstract available

  24. AUTIER P
    Melanoma incidence and COVID-19 lockdowns in the Netherlands.
    Br J Dermatol. 2023 Oct 4:ljad376. doi: 10.1093.

    September 2023
  25. STARK MS, Sturm RA, Pan Y, Smit DJ, et al
    Assessing the genetic risk of nodular melanoma using a candidate gene approach.
    Br J Dermatol. 2023 Sep 28:ljad365. doi: 10.1093.
    PubMed     Abstract available

    Multiple Primary Melanoma: Risk Factors Reviewed.
    Br J Dermatol. 2023 Sep 15:ljad343. doi: 10.1093.

  27. Features of very thin melanoma that predict lymph node involvement.
    Br J Dermatol. 2023;189:e74.

  28. GUERRERO-JUAREZ CF, Goyal PK, Amber KT
    Targeting IL-4/IL-13 in immune checkpoint inhibitor induced bullous pemphigoid: a cautionary note on the beneficial effect of Th2 in melanoma and immunotherapy.
    Br J Dermatol. 2023 Sep 13:ljad324. doi: 10.1093.

  29. PANDEYA N, Dusingize JC, Olsen CM, MacGregor S, et al
    Does genetic risk modify the effect of skin screening on melanoma detection rates?
    Br J Dermatol. 2023 Sep 8:ljad333. doi: 10.1093.
    PubMed     Abstract available

    August 2023

  30. Correction to: Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
    Br J Dermatol. 2023 Aug 24:ljad288. doi: 10.1093.

  31. Validation of a blood test for melanoma.
    Br J Dermatol. 2023;189:e65.

    Real-world data show improved melanoma survival in Sweden.
    Br J Dermatol. 2023 Aug 24:ljad309. doi: 10.1093.

  33. SMITH J, Cust AE, Lo SN
    Risk factors for subsequent primary melanoma for patients with previous melanoma: A systematic review and meta-analysis.
    Br J Dermatol. 2023 Aug 10:ljad275. doi: 10.1093.
    PubMed     Abstract available

    July 2023
  34. PAN CX, Kim DY, Lau CB, Lau WC, et al
    Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: A retrospective cohort study.
    Br J Dermatol. 2023 Jul 28:ljad271. doi: 10.1093.

  35. VIKSTROM S, Mikiver R, Lapins J, Nielsen K, et al
    Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
    Br J Dermatol. 2023 Jul 18:ljad244. doi: 10.1093.
    PubMed     Abstract available

  36. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    PubMed     Abstract available

  37. GIUFFRIDA R, Zanin Poletto G, Guarneri F, Conforti C, et al
    Nevus count on the face for the identification of patients with higher risk of melanoma.
    Br J Dermatol. 2023 Jul 6:ljad216. doi: 10.1093.

  38. RIBERO S, Quaglino P, Roccuzzo G
    Predicting progression in very thin melanoma: the challenge of the next decade?
    Br J Dermatol. 2023 Jul 3:ljad218. doi: 10.1093.

    June 2023
  39. KAKISH H, Sun J, Zheng DX, Ali Ahmed F, et al
    Predictors of Sentinel Lymph Node Metastasis in Very Thin Invasive Melanomas.
    Br J Dermatol. 2023 Jun 8:ljad195. doi: 10.1093.
    PubMed     Abstract available

  40. VERGARA IA, Stark MS
    One Step Closer to Improving Melanoma Diagnosis and Prognosis with Liquid Biopsies.
    Br J Dermatol. 2023 Jun 3:ljad185. doi: 10.1093.

    May 2023
  41. MUTO Y, Kambayashi Y, Kato H, Fukushima S, et al
    Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results.
    Br J Dermatol. 2023 May 27:ljad183. doi: 10.1093.

  42. Two melanoma genes (MITF and MC1R) interact to cause different risks.
    Br J Dermatol. 2023;188:e44.

  43. POGORZELSKA-DYRBUS J, Szepietowski JC
    Melanoma cells in optical super-high magnification dermoscopy.
    Br J Dermatol. 2023 May 22:ljad168. doi: 10.1093.

  44. VAN LAAR R, Latif B, King S, Love C, et al
    Validation of microRNA Liquid Biopsy for Diagnosis and Risk Stratification of Invasive Cutaneous Melanoma.
    Br J Dermatol. 2023 May 5:ljad137. doi: 10.1093.
    PubMed     Abstract available

    April 2023
  45. LALLAS A
    Which melanoma patients are at priority for monitoring to detect new primary melanoma?
    Br J Dermatol. 2023 Apr 17:ljad125. doi: 10.1093.

  46. IBRAHIM LS, Venables ZC, McPhail S, Levell NJ, et al
    Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019.
    Br J Dermatol. 2023 Apr 10:ljad117. doi: 10.1093.

  47. FUJISAWA Y, Namikawa K, Yoshino K, Kiniwa Y, et al
    Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases.
    Br J Dermatol. 2023 Apr 5:ljad114. doi: 10.1093.

    March 2023

  48. Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
    Br J Dermatol. 2023;188:e29.

  49. ASCOTT A, van Bodegraven B, Vernon S, Orteu CH, et al
    The geographical variation of melanoma, basal and squamous cell carcinoma in England.
    Br J Dermatol. 2023 Mar 30:ljad100. doi: 10.1093.

  50. ARACTINGI S, Oules B
    Correcting 'false' warnings with new tools? An illustrative example.
    Br J Dermatol. 2023;188:452.

  51. BRUNO W
    Joint contribution of MC1R and MITF alleles to melanoma risk in the age of polygenic risk scores.
    Br J Dermatol. 2023 Mar 28:ljad097. doi: 10.1093.

  52. NI Y, Watts CG, Scolyer RA, Madronio C, et al
    Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
    Br J Dermatol. 2023 Mar 22:ljad076. doi: 10.1093.

  53. WALLINGFORD CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, et al
    MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
    Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093.
    PubMed     Abstract available

  54. OLSEN CM, Gordon LG, Carter SM, Whiteman DC, et al
    The ethical implications of opportunistic detection of melanoma in clinical care.
    Br J Dermatol. 2023 Mar 3:ljad055. doi: 10.1093.

  55. GHIASVAND R, Berge LAM, Andreassen BK, Green AC, et al
    Statin use and risk of cutaneous melanoma: A nationwide nested case-control study.
    Br J Dermatol. 2023 Mar 3:ljad057. doi: 10.1093.

    February 2023
  56. VAN BODEGRAVEN B, Vernon S, Eversfield C, Board R, et al
    "Get Data Out" Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
    Br J Dermatol. 2023 Feb 23:ljad033. doi: 10.1093.
    PubMed     Abstract available

  57. Skin cancer and ultraviolet-radiation exposure in different jobs.
    Br J Dermatol. 2023;188:e22.

  58. SMITH H, Hussain W
    Is it time we changed the way we manage melanoma in situ of the trunk and limbs?
    Br J Dermatol. 2023 Feb 18:ljad031. doi: 10.1093.

  59. OLSEN CM, Pandeya N, Whiteman DC
    The rise in thick melanomas: can early detection reduce the burden?
    Br J Dermatol. 2023 Feb 15:ljad034. doi: 10.1093.

  60. POIZEAU F, Balusson F, Lemaitre F, Tron C, et al
    The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
    Br J Dermatol. 2023 Feb 10:ljac085. doi: 10.1093.
    PubMed     Abstract available

    January 2023

  61. Patients with melanoma and diabetes benefit from metformin treatment.
    Br J Dermatol. 2023;188:e5.

  62. BERTOLD C, Martel P, Passeron T, Bahadoran P, et al
    Pigmented demodicosis presenting as lentigo maligna diagnosed by reflectance confocal microscopy.
    Br J Dermatol. 2023;188:149-150.

  63. ZHOU L, Shao L, Gao S, Cui C, et al
    Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.
    Br J Dermatol. 2023;188:112-121.
    PubMed     Abstract available

  64. KRAKOWSKI I, Habel H, Nielsen K, Ingvar C, et al
    Association of metformin use and survival in patients with cutaneous melanoma and diabetes.
    Br J Dermatol. 2023;188:32-40.
    PubMed     Abstract available

    December 2022
  65. PERRIER F, Robsahm TE, Ghiasvand R, Borch KB, et al
    No association between physical activity and primary melanoma thickness in a cohort of Norwegian women.
    Br J Dermatol. 2022 Dec 21:ljac136. doi: 10.1093.

    November 2022
  66. HE X, Shi H
    How does acral melanoma respond to immunotherapy?
    Br J Dermatol. 2022 Nov 10:ljac035. doi: 10.1093.

    August 2022
  67. KAWSAR A, Edwards C, Patel P, Heywood RM, et al
    Checkpoint inhibitor associated bullous cutaneous immune related adverse events: a multi-centre observational study.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21836.
    PubMed     Abstract available

  68. BELL KJL, Nijsten T
    Melanoma overdiagnosis: why it matters and what can be done about it.
    Br J Dermatol. 2022 Aug 5. doi: 10.1111/bjd.21750.

    July 2022
  69. NIKOLAOU V, Apalla Z, Carrera C, Fattore D, et al
    Clinical associations and classification of immune checkpoint inhibitors-induced cutaneous toxicities: A multicentric study from the EADV-Task Force of Dermatology for Cancer Patients.
    Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21781.
    PubMed     Abstract available

    June 2022
  70. SANTANDREA G, Valli R, Ragazzi M, Castagnetti F, et al
    Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role.
    Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21715.

  71. CALBET-LLOPART N, Combalia M, Kiroglu A, Potrony M, et al
    Common genetic variants associated with melanoma risk or naevus count in wild-type MC1R melanoma patients.
    Br J Dermatol. 2022 Jun 14. doi: 10.1111/bjd.21707.
    PubMed     Abstract available

    May 2022
  72. RICCI F, Abeni D
    Heterogeneity of reports about the impact of the COVID-19 pandemic on melanoma diagnosis.
    Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21598.

  73. OLSEN CM
    International surveillance of trends in melanoma survival: the impact of morphology.
    Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21651.

  74. KAMMINGA NCW, van der Veldt AAM, Joosen MCW, de Joode K, et al
    Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
    Br J Dermatol. 2022 May 21. doi: 10.1111/bjd.21670.
    PubMed     Abstract available

  75. WHITEMAN DC, Olsen CM, MacGregor S, Law MH, et al
    The effect of screening on melanoma incidence and biopsy rates.
    Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21649.
    PubMed     Abstract available

  76. SCHUMMER P, Schilling B
    How representative are data from global trials on programmed death-1 blockade in melanoma?
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21621.

  77. CARRERA C, Podlipnik S
    Does acral melanoma need a distinctive prognostic staging system?
    Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21585.

  78. WAKKEE M
    Polygenic risk scores for melanoma: a stepwise process towards clinical implementation.
    Br J Dermatol. 2022;186:768.

    April 2022
  79. HARVIMA IT, Harvima RJ
    Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new 'revolutionary' therapeutics?
    Br J Dermatol. 2022 Apr 12. doi: 10.1111/bjd.21583.

    March 2022
  80. KATO J, Namikawa K, Uehara J, Nomura M, et al
    Prognoses of melanoma patients who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: A multicenter retrospective study.
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21276.

  81. DI CARLO V, Stiller CA, Eisemann N, Bordoni A, et al
    Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21274.
    PubMed     Abstract available

  82. KURTANSKY NR, Manci RN, Bello DM, Adamson AS, et al
    Risk of non-acral cutaneous melanoma after the diagnosis of acral melanoma.
    Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21251.

  83. BAI X, Shoushtari AN, Betof Warner A, Si L, et al
    Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study.
    Br J Dermatol. 2022 Mar 16. doi: 10.1111/bjd.21241.
    PubMed     Abstract available

  84. ZAMAGNI F, Bucchi L, Mancini S, Crocetti E, et al
    The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.21051.
    PubMed     Abstract available

  85. PARAGH G
    Epidermal melanoma prognostic factors: a link to paracrine transforming growth factor-beta signalling.
    Br J Dermatol. 2022 Mar 2. doi: 10.1111/bjd.20981.

    February 2022
  86. SANGERS TE, Wakkee M, Kramer-Noels EC, Nijsten T, et al
    Limited impact of COVID-19 related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumor characteristics: A nationwide pathology registry analysis.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21050.
    PubMed     Abstract available

  87. EDEN M, Hainsworth R, Gordon LG, Epton T, et al
    Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21046.
    PubMed     Abstract available

    January 2022
  88. WEI X, Wu D, Chen Y, Li H, et al
    Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21026.
    PubMed     Abstract available

  89. SEMSARIAN CR, Ma T, Nickel B, Scolyer RA, et al
    Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?
    Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21010.

    December 2021
  90. STEINBERG J, Iles MM, Lee JY, Wang X, et al
    Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts.
    Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20956.
    PubMed     Abstract available

    November 2021
  91. SUN MD, Kentley J, Mehta P, Duzsa S, et al
    Accuracy of commercially available smartphone applications for the detection of melanoma.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20903.
    PubMed     Abstract available

  92. COSGAREA I, McConnell AT, Ewen T, Tang D, et al
    Melanoma secretion of TGFbeta-2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration.
    Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20889.
    PubMed     Abstract available

  93. MAEDA T, Hiura A, Uehara J, Toyoshima R, et al
    Early tumor response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20879.
    PubMed     Abstract available

    Do the gut and skin microbiomes share thoughts on melanoma development?
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20811.

    October 2021
  95. HAW WY, Al-Janabi A, Arents BWM, Asfour L, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines.
    Br J Dermatol. 2021;185:736-744.
    PubMed     Abstract available

    September 2021
  96. FROMME JE, Zigrino P
    Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor.
    Br J Dermatol. 2021 Sep 30. doi: 10.1111/bjd.20756.

  97. KIM J, Choi H
    The mucin protein MUCL1 regulates melanogenesis and melanoma genes in a manner dependent on threonine content.
    Br J Dermatol. 2021 Sep 21. doi: 10.1111/bjd.20761.
    PubMed     Abstract available

  98. MAEDA T, Hiura A, Uehara J, Toyoshima R, et al
    Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab-resistant acral and mucosal melanoma.
    Br J Dermatol. 2021 Sep 12. doi: 10.1111/bjd.20758.
    PubMed     Abstract available

  99. LALLAS A, Moscarella E, Kittler H, Longo C, et al
    Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna.
    Br J Dermatol. 2021;185:675-677.

    August 2021
  100. CUST AE
    Strengthening melanoma prevention and early detection among people with type 2 diabetes.
    Br J Dermatol. 2021 Aug 18. doi: 10.1111/bjd.20633.

  101. TSAO H
    Melanoma medicine in the new millennium.
    Br J Dermatol. 2021;185:239-240.

    July 2021
  102. DATZMANN T, Schoffer O, Meier F, Seidler A, et al
    Patients benefit from participating in the German skin cancer screening program? A large cohort study based on administrative data.
    Br J Dermatol. 2021 Jul 21. doi: 10.1111/bjd.20658.
    PubMed     Abstract available

  103. STOER NC, Botteri E, Busund M, Ghiasvand R, et al
    Menopausal hormone therapy and risk of melanoma: a population-based cohort study.
    Br J Dermatol. 2021 Jul 13. doi: 10.1111/bjd.20640.
    PubMed     Abstract available

  104. SCATOLINI M, Patel A, Grosso E, Mello-Grand M, et al
    GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma.
    Br J Dermatol. 2021 Jul 8. doi: 10.1111/bjd.20629.
    PubMed     Abstract available

  105. VITALI F, Colucci R, Di Paola M, Pindo M, et al
    Early melanoma invasivity correlates with gut fungal and bacterial profiles.
    Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20626.
    PubMed     Abstract available

    June 2021
  106. ALTAYEB A, Dawood S, Atwan A, Mills C, et al
    Teledermoscopy: A Helpful Detection Tool for Amelanotic and Hypomelanotic Melanoma.
    Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20609.
    PubMed     Abstract available

    The Role of Interferons in Melanoma Resistance to Immune Checkpoint Blockade: Mechanisms of Escape and Therapeutic Implications.
    Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20608.
    PubMed     Abstract available

  108. WIGGINS J, Polsky D
    Melanoma origins: data from early-stage tumours supports de novo and naevus-associated melanomas as distinct subtypes.
    Br J Dermatol. 2021 Jun 11. doi: 10.1111/bjd.20396.

  109. GUHAN S, Klebanov N, Tsao H
    Melanoma genomics: a state-of-the-art review of practical clinical applications.
    Br J Dermatol. 2021 Jun 6. doi: 10.1111/bjd.20421.
    PubMed     Abstract available

  110. GAO JM, Garioch JJ, Fadhil M, Tan E, et al
    Planning slow Mohs excision margins for lentigo maligna: a retrospective nonrandomized cohort study comparing reflectance confocal microscopy margin mapping vs. visual inspection with dermoscopy.
    Br J Dermatol. 2021;184:1182-1183.

    May 2021
  111. YEH I, Bastian BC
    Melanoma pathology: new approaches and classification.
    Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20427.
    PubMed     Abstract available

    Is consumption of citrus associated with a higher risk of melanoma?
    Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20408.

  113. CLAESON M, Baade P, Marchetti M, Brown S, et al
    Comparative performance of predictors of death from thin (
    Br J Dermatol. 2021 May 12. doi: 10.1111/bjd.20480.
    PubMed     Abstract available

  114. CHEN Y, Andre M, Adhikari K, Blin M, et al
    A GWAS identifies novel gene associations with facial skin wrinkling and mole count in Latin-Americans.
    Br J Dermatol. 2021 May 6. doi: 10.1111/bjd.20436.
    PubMed     Abstract available

    April 2021
  115. DOUSSET L, Martins C, Jacquemin C, Amico S, et al
    Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with high frequency of melanoma-infiltrating CXCR3(+) resident memory CD8(+) T cells and multiple chemokine pathways.
    Br J Dermatol. 2021 Apr 24. doi: 10.1111/bjd.20405.
    PubMed     Abstract available

  116. DESSINIOTI C, Geller AC, Whiteman DC, Garbe C, et al
    Not all melanomas are created equal: A review and call for more research into nodular melanoma.
    Br J Dermatol. 2021 Apr 16. doi: 10.1111/bjd.20388.
    PubMed     Abstract available

  117. KITTLER H
    Total body photography for secondary prevention of melanoma.
    Br J Dermatol. 2021 Apr 6. doi: 10.1111/bjd.20058.

  118. AGRAWAL R, Tso S, Eltigani EA, Busam KJ, et al
    PRAME immunohistochemistry as an adjunct in the diagnosis of paucicellular lentigo maligna in a young man.
    Br J Dermatol. 2021;184:e122.

    March 2021
  119. MARLEY AR, Li M, Champion VL, Song Y, et al
    The Association between Citrus Consumption and Melanoma Risk in the UK Biobank.
    Br J Dermatol. 2021 Mar 30. doi: 10.1111/bjd.19896.
    PubMed     Abstract available

    Divergent pathways for melanoma: what is the role of genetics?
    Br J Dermatol. 2021 Mar 25. doi: 10.1111/bjd.19887.

  121. PEREZ M, Chakraborty A, Lau LS, Mohammed NBB, et al
    Melanoma-associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19891.
    PubMed     Abstract available

  122. EL SHAROUNI MA, Varey AHR, Witkamp AJ, Ahmed T, et al
    Predicting sentinel node positivity in melanoma patients: external validation of a risk-prediction calculator (the MIA nomogram) using a large European population-based patient cohort.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19895.
    PubMed     Abstract available

    February 2021
  123. WOLNER ZJ, Flowers NI, Yushak ML, Chen SC, et al
    Exploring the melanoma survivorship experience: a qualitative study.
    Br J Dermatol. 2021 Feb 5. doi: 10.1111/bjd.19868.
    PubMed     Abstract available

    January 2021
  124. DESSINIOTI C, Geller AC, Stergiopoulou A, Dimou N, et al
    A multicenter study of nevus-associated melanoma versus de novo melanoma, tumor thickness and body site differences.
    Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19819.
    PubMed     Abstract available

  125. NAGORE E, Martinez-Garcia MA, Gomez-Olivas JD, Manrique-Silva E, et al
    Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: An observational multi-centric study in 443 patients with melanoma.
    Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19813.
    PubMed     Abstract available

  126. GAULT A, Anderson AE, Plummer R, Stewart C, et al
    Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
    Br J Dermatol. 2021 Jan 4. doi: 10.1111/bjd.19750.
    PubMed     Abstract available

    December 2020
  127. TOLAND AE
    The influence of sex, age and sunlight exposure on mutational processes in melanoma.
    Br J Dermatol. 2020 Dec 28. doi: 10.1111/bjd.19336.

  128. JI-XU A, Dinnes J, Matin RN
    Total Body Photography for the Diagnosis of Cutaneous Melanoma in Adults: A Systematic Review and Meta-Analysis.
    Br J Dermatol. 2020 Dec 28. doi: 10.1111/bjd.19759.
    PubMed     Abstract available

  129. VUONG K, Armstrong BK, Espinoza D, Hopper JL, et al
    An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study.
    Br J Dermatol. 2020 Dec 3. doi: 10.1111/bjd.19706.
    PubMed     Abstract available

  130. LASKAR R, Ferreiro-Iglesias A, Bishop DT, Iles MM, et al
    Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity.
    Br J Dermatol. 2020 Dec 3. doi: 10.1111/bjd.19705.
    PubMed     Abstract available

    November 2020
  131. NAKAMURA M, Obayashi M, Yoshimitsu M, Kato H, et al
    Comparative whole-exome sequencing of an ultra-late recurrent malignant melanoma.
    Br J Dermatol. 2020 Nov 18. doi: 10.1111/bjd.19680.
    PubMed     Abstract available

    October 2020
  132. CHARVET E, Kramkimel N, Chaplain L, Gantzer A, et al
    Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-PD-1 monoclonal antibodies.
    Br J Dermatol. 2020 Oct 24. doi: 10.1111/bjd.19629.
    PubMed     Abstract available

  133. GHIASVAND R, Khosrotehrani K, Hughes MCB, von Schuckmann LA, et al
    Patient age and risk of recurrence of primary melanoma at high risk of spread.
    Br J Dermatol. 2020 Oct 14. doi: 10.1111/bjd.19601.
    PubMed     Abstract available

  134. MINIOTTI M, Ribero S, Leombruni P
    Targeting fear of recurrence: the advantages of assessing psychosocial attributes and psychological dispositions.
    Br J Dermatol. 2020;183:789-790.

  135. HAUGAARD JH, Egeberg A
    Do we need to fear methotrexate?
    Br J Dermatol. 2020;183:608-609.

    September 2020
  136. BLANKENSTEIN SA, van Akkooi ACJ
    Broadening indications for neoadjuvant immunotherapy.
    Br J Dermatol. 2020;183:421-422.

    August 2020
  137. NAPOLITANO M, Caiazzo G, Fabbrocini G, Balato A, et al
    Increased expression of IL-23A in lesional skin of atopic dermatitis patients with psoriasiform reaction during dupilumab treatment.
    Br J Dermatol. 2020 Aug 6. doi: 10.1111/bjd.19464.
    PubMed     Abstract available

    July 2020
  138. SHEEN YS, Chu CY
    Co-occurrence of TERT promotor mutations with BRAF or NRAS alterations correlates with worse prognosis in melanoma.
    Br J Dermatol. 2020 Jul 22. doi: 10.1111/bjd.19416.

  139. ALFONSO JH, Martinsen JI, Weiderpass E, Pukkala E, et al
    Occupation and cutaneous melanoma: a 45-year historical cohort study of 14.9 million people in five Nordic countries.
    Br J Dermatol. 2020 Jul 6. doi: 10.1111/bjd.19379.
    PubMed     Abstract available

    May 2020
    Immune checkpoint blockade: an urgent call for biomarkers to help guide treatment.
    Br J Dermatol. 2020;182:1085-1086.

    March 2020
  141. ROBINSON JK, Abou-El-Seoud D, Reavy R, Turrisi R, et al
    Persistence of partner-assisted skin self-examination supported by "being in this together": a randomized trial.
    Br J Dermatol. 2020 Mar 28. doi: 10.1111/bjd.19048.
    PubMed     Abstract available

    December 2019
  142. HARTMAN RI, Xue Y, Singer S, Markossian TW, et al
    Modeling the Value of Risk Stratified Skin Cancer Screening of Asymptomatic Patients by Dermatologists.
    Br J Dermatol. 2019 Dec 22. doi: 10.1111/bjd.18816.
    PubMed     Abstract available

    March 2019
  143. ROBERTS MR, Asgari MM, Toland AE
    Genome-wide association studies and polygenic risk scores for skin cancer: clinically useful yet?
    Br J Dermatol. 2019 Mar 25. doi: 10.1111/bjd.17917.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.